|
注册号: Registration number: |
ChiCTR2500115108 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-22 18:03:51 |
|
注册时间: Date of Registration: |
2025-12-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
评价不同手术方式在血浆基质骨块用于水平骨增量的有效性的多中心、随机对照、单盲临床研究 |
|
Public title: |
A multicenter, randomized controlled, single-blind clinical study evaluating the effectiveness of different surgical methods using plasma-based bone blocks for horizontal bone augmentation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
评价不同手术方式在血浆基质骨块用于水平骨增量的有效性的多中心、随机对照、单盲临床研究 |
|
Scientific title: |
A multicenter, randomized controlled, single-blind clinical study evaluating the effectiveness of different surgical methods using plasma-based bone blocks for horizontal bone augmentation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
范启航 |
研究负责人: |
张玉峰 |
|
Applicant: |
Qihang Fan |
Study leader: |
Yufeng Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 139 8620 5840 |
研究负责人电话:
Study leader's |
+86 186 0719 8656 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
370117016@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zyf@whu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市洪山区珞喻路237号 |
研究负责人通讯地址: |
湖北省武汉市洪山区珞喻路237号 |
|
Applicant address: |
No. 237, Luoyu Road, Hongshan District, Wuhan City, Hubei Province |
Study leader's address: |
No. 237, Luoyu Road, Hongshan District, Wuhan City, Hubei Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
武汉大学口腔医院 |
||
|
Applicant's institution: |
School of Stomatology Wuhan University |
||
|
研究负责人所在单位: |
武汉大学口腔医院 |
||
|
Affiliation of the Leader: |
School of Stomatology Wuhan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[WDKQ2024]伦审字(D04)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
武汉大学口腔医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of School & Hospital of Stomatology, Wuhan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-10 00:00:00 | ||
|
伦理委员会联系人: |
丁洁 |
||
|
Contact Name of the ethic committee: |
Jie Ding |
||
|
伦理委员会联系地址: |
湖北省武汉市洪山区珞喻路237号 |
||
|
Contact Address of the ethic committee: |
No. 237, Luoyu Road, Hongshan District, Wuhan City, Hubei Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 8768 6250 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
武汉大学口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of Stomatology Wuhan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市洪山区珞喻路237号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 237, Luoyu Road, Hongshan District, Wuhan City, Hubei Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised |
||||||||||||||||||||||
|
研究疾病: |
水平骨缺损 |
||||||||||||||||||||||
|
Target disease: |
horizontal bone defect |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
采用血浆基质骨块进行水平骨增量时,比较是否应用膜钉对治疗效果的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
When using plasma-based bone blocks for horizontal bone augmentation, compare the impact of whether membrane screws are applied on the treatment outcome |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1) 妊娠、哺乳期女性及研究期间计划怀孕的患者; (2) 患有口腔外科手术禁忌症的患者; (3) 患有系统性疾病可能影响术后愈合期和/或骨结合者,如控制不良糖尿病(空腹血糖值>6.8mmol/L),未控制的高血压(收缩压≥160mmHg和/或舒张压≥100mmHg),软骨病,甲状腺疾病等; (4) 系统或局部的骨性疾病,如骨结核,骨炎,骨肿瘤等; (5) 手术区域临近牙齿具有根尖症的患者,或者手术区域临近牙齿有根尖囊肿的患者; (6) 全身有未控制的感染; (7) 严重血液系统疾病,如白血病或其它出血性疾病; (8) 尚未控制的邻牙牙周病、晚期牙周病患者; (9) 已知或疑似恶性肿瘤; (10)近3年内有头部及颈部的放射治疗或化学治疗病史,或者正在进行放射治疗或化学治疗的患者; (11)正在服用或长期服用可能影响术后愈合或骨结合的特殊药物者(如:二磷酸盐类药物和高剂量的肾上腺皮质激素); (12)肝肾功能异常(肝ALT和AST值超过正常值上限的1.5倍,或肌酐超过正常值上限的1.5倍); (13)酗酒、吸毒或其他药物成瘾者或者有成瘾倾向者; (14)吸烟超过每日十支者; (15)乙肝急性感染期患者(大三阳); (16)HIV抗体初筛、丙肝抗体、梅毒螺旋体特异性抗体检测阳性者; (17)不满足种植体修复要求的患者(如:对金属过敏); (18)研究者认为因其他原因不适宜参加本次临床试验者。 (19)术区存在垂直向骨缺损且需要进行垂直骨增量的患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Pregnant or lactating women and patients planning to conceive during the study period; (2) Patients with contraindications to oral surgery; (3) Patients with systemic diseases that may affect the postoperative healing period and/or bone integration, such as poorly controlled diabetes (fasting blood glucose > 6.8 mmol/L), uncontrolled hypertension (systolic blood pressure >= 160 mmHg and/or diastolic blood pressure >= 100 mmHg), osteochondrosis, thyroid diseases, etc.; (4) Systemic or local bone diseases, such as bone tuberculosis, osteomyelitis, bone tumors, etc.; (5) Patients with teeth in the surgical area having periapical diseases, or teeth in the surgical area having periapical cysts; (6) Patients with uncontrolled systemic infections; (7) Severe hematological diseases, such as leukemia or other bleeding disorders; (8) Patients with uncontrolled periapical periodontal disease or advanced periodontal disease; (9) Known or suspected malignant tumors; (10) Patients with a history of radiation therapy or chemotherapy in the head and neck region within the past 3 years, or those undergoing radiation therapy or chemotherapy; (11) Patients currently taking or long-term taking special drugs that may affect postoperative healing or bone integration (such as bisphosphonate drugs and high-dose adrenal corticosteroids); (12) Patients with abnormal liver and kidney function (ALT and AST values exceeding 1.5 times the upper limit of normal, or creatinine exceeding 1.5 times the upper limit of normal); (13) Alcoholics, drug addicts or those with addictive tendencies; (14) Smokers who smoke more than 10 cigarettes per day; (15) Patients in the acute stage of hepatitis B (Big Three Positive); (16) Patients with positive initial screening for HIV antibodies, hepatitis C antibodies, and specific antibodies for Treponema pallidum; (17) Patients who do not meet the requirements for implant restoration (such as being allergic to metals); (18) Patients considered by the researchers to be unsuitable to participate in this clinical trial for other reasons; (19) Patients with vertical bone defects in the surgical area and requiring vertical bone augmentation. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-01 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由一名实验人员使用随机数字表进行随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomization was performed by an experimenter using a table of random numbers |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲(对受试者隐藏分组),对评估者隐藏分组 |
|
Blinding: |
Single-blind (with the groups concealed from the subjects), and blind to the groups from the evaluators |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
计划于研究结束后12个月,采用临床试验公共管理平台并向公众开放查询。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
It is planned to adopt the clinical trial public management platform and make it available to the public twelve months after the end of the study |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本项目所有数据提取表、汇总表均要求经办人员签字并记录时间,保证数据收集完整、可溯源。此外,本项目实施全程将注重患者、医生相关个人隐私的保护,采用匿名形式对全部信息及原始数据进行记录。此外,全部原始数据将保存于指定的加密硬盘,由专人负责保管。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All data extraction tables and summary tables of this project require the handling personnel to sign and record the time, so as to ensure that the data collection is complete and traceable. In addition, the whole implementation of this project will pay attention to the protection of patients' and doctors' personal privacy, and record all information and original data in anonymous form. In addition, all the original data will be stored in the designated encrypted hard disk, which is responsible for safekeeping. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |